An Early Exploratory Clinical Study of the Safety, Tolerability, and Preliminary Efficacy of JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs JY 231 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Encephalitis; Multiple sclerosis; Myasthenia gravis; Myositis; Neuromyelitis optica
- Focus Adverse reactions
- 03 Feb 2025 New trial record